Haleon Pakistan Limited
PPSX:HALEON670.64
PKR
-7.09
(-1.05%)
ISIN
PK0112101016
Return %
Stock
S&P 500
1Y
-28.69
14.20
3Y
319.15
81.12
5Y
152.92
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Qawi Naseer
- Full Time Employees
- 447
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Karachi Pakistan
- IPO Date
- Mar 22, 2017
- Website
- haleon.pk.com
- Similar Companies
- Business
- Haleon Pakistan Limited is a consumer healthcare company that engages in the development, manufacturing, marketing, and distribution of over-the-counter pharmaceuticals, oral care solutions, and nutritional health products. The company operates across four primary business segments: Pain Relief, offering oral and topical analgesics under the Panadol, Panadol Extra, Panadol Extend, and Voltral brands; Oral Health, providing therapeutic sensitivity toothpastes, daily gum care treatments, and oral hygiene products under the Sensodyne and Parodontax brands; Wellness and Nutrition, delivering dietary supplements, multivitamins, and gastrointestinal treatments including CaC-1000 Plus, Centrum, Qalsium-D, and ENO antacid; and Respiratory Health, featuring cough, cold, sinus, and allergy formulations under the Panadol CF, Panadol CF Day, and T-Day brands, in addition to topical dermatological formulations such as Hydrozole. Incorporated in 2015 and headquartered in Karachi, Pakistan, the company operates as a subsidiary of Haleon Netherlands B.V., with United Kingdom-based Haleon plc serving as the ultimate parent entity. Haleon Pakistan serves retail pharmacies, grocery chains, hospital networks, and wholesale distributors nationwide, supported by its primary manufacturing and packaging facility located in Jamshoro, Sindh. In recent strategic developments, the company rebranded from GlaxoSmithKline Consumer Healthcare Pakistan Limited to Haleon Pakistan Limited following the global demerger and listing of Haleon plc. The company has implemented significant capital expenditure programs to expand production capacity and technological infrastructure at its Jamshoro plant, scaling output for its flagship Panadol portfolio and establishing the site as a regional export manufacturing hub targeting distribution across 19 international markets. Furthermore, the company expanded its commercial wellness portfolio through the local market introduction of Centrum multivitamins, secured TRUE Platinum Zero Waste certification for its Jamshoro industrial operations, and advanced corporate social health alliances, including partnerships with Smile Train to fund pediatric surgical care.